Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $237.60 Analyst target: $238.17 Upside: 0.24%
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.
See the full interactive analysis & chart →Informational only — not investment advice.